Severe Thrombocytopenia in a Patient With Lung Adenocarcinoma Severe Thrombocytopenia in a Patient With Lung Adenocarcinoma
This case of severe grade V thrombocytopenia caused by nivolumab highlights the need for clinicians to be aware of this potential adverse effect of immune-checkpoint inhibitors.Journal of Medical Case Reports
CONCLUSIONS: Our results confirm the efficacy and safety of a first line regimen comprising gemcitabine and Nab-paclitaxel in metastatic PDAC in a real-life population. PMID: 32957885 [PubMed - as supplied by publisher]
Conclusions Pegilodecakin+FOLFOX had an acceptable tolerability profile in PDAC, with no substantial irAEs seen, and promising efficacy with the combination yielding a 2-year OS of 24% (95% CI 10 –42). These data led to the phase 3 study with pegilodecakin+FOLFOX as second-line therapy of PDAC (SEQUOIA).
CONCLUSION: Palbociclib has limited single-agent activity in gastroesophageal tumors. PMID: 32692450 [PubMed - as supplied by publisher]
AbstractBackground/AimsPediatric immune thrombocytopenia (ITP) is an autoimmune disease; whose etiology is not exactly understood and seems to be highly multifactorial. Long non ‐coding RNAs (lncRNAs) are key regulators of different actions, which contribute to the development of many autoimmune diseases. To gain a further understanding, we estimated the relative expression of lncRNAs Metastasis‐associated lung adenocarcinoma transcript 1 (MALAT1) and tumor necrosis fac tor‐α (TNF‐α) and heterogeneous nuclear ribonucleoprotein L (hnRNPL) immune‐regulatory lncRNA (THRIL) in pediatric ITP.MethodsIn this...
ConclusionsBevacizumab plus chemotherapy is highly effective with acceptable toxicities in nonsquamous NSCLC patients with uncontrolled MPE, and should be considered as a standard therapy in this setting.Key pointsSignificant findings of the studyBevacizumab plus chemotherapy is highly effective with acceptable toxicities in nonsquamous NSCLC patients with uncontrolled MPE.What this study addsBevacizumab plus chemotherapy should be considered as a standard treatment option for patients with uncontrolled MPE.Clinical trial registrationUMIN000006868 was a phase II study of efficacy of bevacizumab plus chemotherapy for the ma...
CONCLUSIONS: In summary, there is no evidence of a demonstrable overall survival benefit with the addition of anti-EGFR therapy in first-line and recurrent glioblastomas. Newer drugs that are specially designed for glioblastoma targets may raise the possibility of success in this population, but data are lacking at present. Future studies should be more selective in pursuing people displaying specific EGFR targets. PMID: 32395825 [PubMed - in process]
CONCLUSION: Antibacterial exposure was associated with an increased risk of gemcitabine-associated, dose-limiting adverse events, including aggregate hematologic and gastrointestinal events, as well as four specific hematologic adverse events, suggesting that intratumor bacteria may be responsible for a clinically significant portion of gemcitabine metabolism. Alternative avenues of evidence will be necessary to confirm this preliminary finding and assess its generalizability. There is plentiful opportunity for similar analyses on other clinical trial data sets, where gemcitabine or other biomimetic small molecules were us...
Conclusion: For patients with LAC, ACT combined with CHMF after radical surgery can prolong the DFS time especially in the early stage, and reduces the chemotherapy-related toxic and side effects. Trial Registration: NCT01441752. Registered 14 July, 2011. PMID: 32140080 [PubMed]
Conclusions: This study showed bevacizumab combined with chemotherapy could effectively control intracranial lesions, relieve symptoms, and improve the quality of life and survival of patients with brain metastases from lung adenocarcinoma. Serum baseline VEGF may be a predictor of efficacy of bevacizumab plus chemotherapy in the treatment of brain metastases from lung adenocarcinoma. PMID: 31903262 [PubMed]
ConclusionA very difficult case of grade V immune-related thrombocytopenia after the administration of nivolumab as second-line therapy for relapsed lung adenocarcinoma was described. Immune-related thrombocytopenia is a rare adverse event, but it must be considered a possible complication because it may become critical once it has occurred.